Domů › Nemalobuněčný plicní karcinom › Minnesota › Duluth
Klinické studie Nemalobuněčný plicní karcinom v Duluth, MN
13 studií pro Nemalobuněčný plicní karcinom hledá účastníky v lokalitách v Duluth a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Probíhá náborFáze 3
- Essentia Health Cancer Center, Duluth
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Probíhá náborFáze 2
- Essentia Health Cancer Center, Duluth
- Essentia Health Saint Mary's Medical Center, Duluth
- Miller-Dwan Hospital, Duluth
- a dalších 1
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Probíhá náborFáze 3
- Essentia Health Cancer Center, Duluth
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Probíhá náborFáze 1/2
- St. Luke'S /ID# 273344, Duluth
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- Research Site, Duluth
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Probíhá náborFáze 3
- Clinical Study Sites, Duluth
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Probíhá náborFáze 3
- Miller-Dwan Hospital, Duluth
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- Essentia Health Cancer Center, Duluth
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2
- Essentia Health Cancer Center, Duluth
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2/3
- Essentia Health Cancer Center, Duluth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Probíhá náborObservační studie
- Essentia Health Cancer Center, Duluth
- Saint Luke's Hospital of Duluth, Duluth
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Duluth
Studie Nemalobuněčný plicní karcinom v jiných městech
- Houston, TX145 studií
- New York City, NY120 studií
- Arlington, VA104 studií
- Nashville, TN97 studií
- Boston, MA90 studií
- Los Angeles, CA87 studií
- St. Louis, MO73 studií
- Chicago, IL61 studií
- Baltimore, MD60 studií
- San Antonio, TX59 studií
- Columbus, OH56 studií
- Washington, DC55 studií
Další studie v Duluth
- Rakovina plic11 studií
- Rakovina prostaty7 studií
- Rakovina prsu7 studií
- Rakovina tlustého střeva6 studií
- Rakovina močového měchýře6 studií
- Akutní myeloidní leukemie6 studií
- Rakovina endometria5 studií
- Rakovina žaludku5 studií
- Rakovina konečníku5 studií
- Rakovina jícnů5 studií
- Rakovina hrtanu5 studií
- Melanom5 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.